Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
Patient experienced constipation; Case reference number US-BN-2024-002825 is a spontaneous case initially received from consumer via Med Communications (reference number: USBAV24-3166) on 02-Dec-2024 and concerns a 39-year-old male patient. The patient's medical history and concomitant medication details were not provided. The patient's current medical condition included pork allergy. On 30-Nov-2024, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for typhoid immunization. On unspecified date, unknown amount of time after taking the first dose, the patient experienced constipation. As reported, the pork constipated him, and it had the effect on him. The reporter would like to check the composition of the gelatin capsules and if there was any ingredient originated from beef. On 02-Dec-2024, reported as tonight, the patient was due for another dose of Vivotif. At the time of the initial report, it was unknown if the patient recovered from event of the constipation. The reporter assessed the event of constipation as non-serious, and causality for the event was reported as possible. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241202-287a8e to US-BAVARIAN NORDIC A/S-US-BN-2024-002825, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A 39-year-old male patient experienced constipation within approximately one month after taking the first dose of Vivotif (administered at an unknown dose, orally, for typhoid immunization). Constipation is listed according to CCDS v8 however unexpected according to USPI. The outcome was unknown. The patient's medical history and concomitant medication details were not provided while current medical condition included pork allergy. Causality is assessed as related due to known product safety profile, lack of alternative explanation and since contributory role of suspect product cannot be excluded. The case is non-serious.; Sender's Comments: A 39-year-old male patient experienced constipation within approximately one month after taking the first dose of Vivotif (administered at an unknown dose, orally, for typhoid immunization). Constipation is listed according to CCDS v8 however unexpected according to USPI. The outcome was unknown. The patient's medical history and concomitant medication details were not provided while current medical condition included pork allergy. Causality is assessed as related due to known product safety profile, lack of alternative explanation and since contributory role of suspect product cannot be excluded. The case is non-serious.
Meat allergy